Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,437

Participants

Timeline

Start Date

December 10, 2018

Primary Completion Date

December 14, 2023

Study Completion Date

July 31, 2024

Conditions
Critical Illness
Interventions
DRUG

Dexmedetomidine

"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."

DRUG

Clonidine

"Patients will commence intravenous infusion of open-label study drug according to a weight-based dose regimen as early as possible post-randomisation, and within a maximum of two hours.~Bedside clinical staff will transition patients to achieve sedation with the allocated α2-agonist agent as quickly as clinically feasible and safe, to replicate the way these drugs would be used in routine practice. Additional opiate will be used for analgesia using clinical judgement. Once established, additional propofol will only be used when the maximum α2-agonist dose is reached or because cardiovascular or other side-effects limit dose escalation."

DRUG

Propofol

Patients will continue to receive intravenous propofol according to current usual care.

Trial Locations (38)

Unknown

Belfast Health & Social Care Trust, Belfast

South Eastern Health and Social Trust, Belfast

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool

North Bristol NHS Trust, Bristol

University Hospitals Bristol NHS Foundation Trust, Bristol

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Cardiff and Vale University Health Board, Cardiff

Countess of Chester Hospital NHS Foundation Trust, Chester

The Dudley Group NHS Foundation Trust, Dudley

NHS Dumfries and Galloway, Dumfries

NHS Lothian, Edinburgh

Medway NHS Foundation Trust, Gillingham

NHS Greater Glasgow and Clyde, Glasgow

Harrogate and District NHS Trust, Harrogate

Wye Valley NHS Trust, Hereford

The Queen Elizabeth Hospital Kings Lynn NHS Foundation Trust, Kings Lynn

Leeds Teaching Hospitals NHS Trust, Leeds

University Hospitals of Leicester, Leicester

Lewisham and Greenwich NHS Trust, Lewisham

Aintree University Hospital Foundation Trust, Liverpool

Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool

Guys and St Thomas NHS Foundation Trust, London

Imperial College Healthcare NHS Trust, London

King's College Hospital NHS Foundation Trust, London

St George's University Hospitals NHS Foundation Trust, London

The Royal Marsden NHS Foundation Trust, London

University College London Hospitals NHS Foundation Trust, London

Manchester University Foundation Trust, Manchester

The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle

Aneurin Bevan University Health Board, Newport

Nottingham University Hospitals NHS Trust, Nottingham

Oxford University Hospitals NHS Foundation Trust., Oxford

Poole Hospitals NHS Foundation Trust, Poole

University Hospital Southampton NHSFT, Southampton

North Tees and Hartlepool NHS Foundation Trust, Stockton-on-Tees

Taunton and Somerset NHS Foundation Trust, Taunton

West Hertfordshire Hospitals NHS Trust, Watford

All Listed Sponsors
collaborator

West Hertfordshire Hospitals NHS Trust

OTHER

collaborator

Queen's University, Belfast

OTHER

collaborator

The University of Queensland

OTHER

collaborator

University Hospital of Wales

OTHER

collaborator

Edinburgh Napier University

OTHER

collaborator

King's College London

OTHER

collaborator

University of Warwick

OTHER

collaborator

University of Manchester

OTHER

collaborator

Royal Surrey County Hospital NHS Foundation Trust

OTHER

collaborator

University College, London

OTHER

collaborator

NHS Lothian

OTHER_GOV

collaborator

Imperial College London

OTHER

collaborator

University of Cambridge

OTHER

lead

University of Edinburgh

OTHER

NCT03653832 - Alpha 2 Agonists for Sedation to Produce Better Outcomes From Critical Illness (A2B Trial) | Biotech Hunter | Biotech Hunter